Therapeutic application of CCK2R-targeting PP-F11: influence of particle range, activity and peptide amount

Psychonomic Bulletin and Review

Volumn 4, Issue 1, 1997, Pages

  Konijnenberg, Mark W ^a   Breeman, Wout A P ^a   de Blois, Erik ^a   Chan, Ho Sze ^a   Boerman, Otto C ^b   Laverman, Peter ^b   Kolenc Peitl, Petra ^c   Melis, Marleen ^a   de Jong, Marion ^a  

^a ERASMUS MEDICAL CENTER   (Netherlands)

^b RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

^c UNIVERSITY MEDICAL CENTRE LJUBLJANA   (Slovenia)

Author keywords

Bi 213; CCK2 peptide receptor saturation; Minigastrin; Preclinical radionuclide dosimetry; Radiobiology; Specific activity; Tumour cure model; Y 90, Lu 177

Indexed keywords

EID: 84930816133     PISSN: 10699384     EISSN: 15315320     Source Type: Journal    
DOI: 10.1186/s13550-014-0047-1     Document Type: Article

References (40)

1. Laverman P, Joosten L, Eek A, Roosenburg S, Peitl PK, Maina T, Macke H, Aloj L, von Guggenberg E, Sosabowski JK, de Jong M, Reubi JC, Oyen WJ, Boerman OC: Comparative biodistribution of 12 (1)(1)(1)In-labelled gastrin/CCK2 receptor-targeting peptides.Eur J Nucl Med Mol Imaging 2011, 38:1410–1416.
2. Aloj L, Aurilio M, Rinaldi V, D'Ambrosio L, Tesauro D, Peitl PK, Maina T, Mansi R, von Guggenberg E, Joosten L, Breeman WA, De Blois E, Koelewijn S, Melis M, Waser B, Beetschen K, Reubi JC, de Jong M: Comparison of the binding and internalization properties of 12 DOTA-coupled and (1)(1)(1)In-labelled CCK2/gastrin receptor binding peptides: a collaborative project under COST Action BM0607.Eur J Nucl Med Mol Imaging 2011, 38:1417–1425.
3. O'Donoghue JA, Bardiès M, Wheldon TE: Relationships between tumor size and curability for uniformly targeted therapy with beta-emitting radionuclides.J Nucl Med 1995, 36:1902–1909.
4. Morgenstern A, Bruchertseifer F, Apostolidis C: Bismuth-213 and actinium-225-generator performance and evolving therapeutic applications of two generator-derived alpha-emitting radioisotopes.Curr Radiopharm 2012, 5:221–227.
5. de Jong M, Breeman W, Bernard B, Bakker W, Visser T, Kooij P, van Gameren A, Krenning E: Tumor response after [(90)Y-DOTA(0), Tyr(3)]octreotide radionuclide therapy in a transplantable rat tumor model is dependent on tumor size.J Nucl Med 2001, 42:1841–1846.
6. de Jong M, Breeman WAP, Bernard BF, Bakker WH, Schaar M, van Gameren A, Bugaj JE, Erion J, Schmidt M, Srinivasan A, Krenning EP: [177Lu-DOTA(0), Tyr3] octreotate for somatostatin receptor-targeted radionuclide therapy.Int J Cancer 2001, 92:628–633.
7. 177Lu at high specific activities.Eur J Nucl Med Mol Imaging 2003, 30:917–920.
8. Breeman WA, Kwekkeboom DJ, Kooij PP, Bakker WH, Hofland LJ, Visser TJ, Ensing GJ, Lamberts SW, Krenning EP: Effect of dose and specific activity on tissue distribution of indium-111-pentetreotide in rats.J Nucl Med 1995, 36:623–627.
9. de Jong M, Breeman WA, Bernard BF, van Gameren A, de Bruin E, Bakker WH, van der Pluijm ME, Visser TJ, Macke HR, Krenning EP: Tumour uptake of the radiolabelled somatostatin analogue [DOTA0, TYR3]octreotide is dependent on the peptide amount.Eur J Nucl Med 1999, 26:693–698.
10. 111In-DTPA-D-Phe1-octreotide in tumor-bearing nude mice: influence of amount injected and route of administration.Nucl Med Biol 2003, 30:253–260.
11. Kletting P, Muller B, Erentok B, Schmaljohann J, Behrendt FF, Reske SN, Mottaghy FM, Glatting G: Differences in predicted and actually absorbed doses in peptide receptor radionuclide therapy.Med Phys 2012, 39:5708–5717.
12. Kolenc-Peitl P, Mansi R, Tamma M, Gmeiner-Stopar T, Sollner-Dolenc M, Waser B, Baum RP, Reubi JC, Maecke HR: Highly improved metabolic stability and pharmacokinetics of indium-111-DOTA-gastrin conjugates for targeting of the gastrin receptor.J Med Chem 2011, 54:2602–2609.
13. X-MC Team: MCNP - a general Monte Carlo N-particle transport code, version 5 vol. I: Overview and theory. In Los Alamos National Lab Report: LA-UR-03-1987. 2003. https://laws.lanl.gov/vhosts/mcnp.lanl.gov/references.shtml#mcnp5_refs.
14. Wambersie A: ICRU Report 44: Tissue Substitutes in Radiation Dosimetry and Measurement. Bethesda (US): International Commission on Radiation Units and measurements; 1989.
15. Eckerman K, Endo A: MIRD: Radionuclide Data and Decay Schemes. 2nd edition. Reston (US): Society of Nuclear Medicine and Molecular Imaging; 2008.
16. Koivunoro H, Siiskonen T, Kotiluoto P, Auterinen I, Hippelainen E, Savolainen S: Accuracy of the electron transport in mcnp5 and its suitability for ionization chamber response simulations: a comparison with the egsnrc and penelope codes.Med Phys 2012, 39:1335–1344.
17. Schaart DR: The scaling method applied to beta particle line sources with a finite diameter.Med Phys 2002, 29:2682–2686.
18. Bolch WE, Eckerman KF, Sgouros G, Thomas SR: MIRD pamphlet no. 21: a generalized schema for radiopharmaceutical dosimetry–standardization of nomenclature.J Nucl Med 2009, 50:477–484.
19. 213Bi-DOTATOC for peptide receptor alpha-therapy of GEP-NET patients refractory to beta therapy.J Nucl Med 2012, 53(Supplement 1):455.
20. Joiner M, van der Kogel A: Basic clinical radiobiology. London: Hodder Arnold; 2009.
21. Dale RG: Dose-rate effects in targeted radiotherapy.Phys Med Biol 1996, 41:1871–1884.
22. Malaise EP, Fertil B, Chavaudra N, Guichard M: Distribution of radiation sensitivities for human tumor cells of specific histological types: comparison of in vitro to in vivo data.Int J Radiat Oncol Biol Phys 1986, 12:617–624.
23. Ling CC, Gerweck LE, Zaider M, Yorke E: Dose-rate effects in external beam radiotherapy redux.Radiother Oncol 2010, 95:261–268.
24. Wang JZ, Li XA: Impact of tumor repopulation on radiotherapy planning.Int J Radiat Oncol Biol Phys 2005, 61:220–227.
25. Solomon B, Hagekyriakou J, Trivett MK, Stacker SA, McArthur GA, Cullinane C: EGFR blockade with ZD1839 (“Iressa”) potentiates the antitumor effects of single and multiple fractions of ionizing radiation in human A431 squamous cell carcinoma. Epidermal growth factor receptor.Int J Radiat Oncol Biol Phys 2003, 55:713–723.
26. 177Lu in human pancreatic adenocarcinoma cells.Nucl Med Biol 2007, 34:185–193.
27. 68Ga]-DOTATOC to somatostatin receptors in neuroendocrine tumours–impact of peptide mass.Nucl Med Biol 2010, 37:265–275.
28. 68Ga-DOTA-octreotate: implications for peptide receptor radionuclide therapy.Eur J Nucl Med Mol Imaging 2012, 39:50–56.
29. Breeman WA, Hofland LJ, de Jong M, Bernard BF, Srinivasan A, Kwekkeboom DJ, Visser TJ, Krenning EP: Evaluation of radiolabelled bombesin analogues for receptor-targeted scintigraphy and radiotherapy.Int J Cancer 1999, 81:658–665.
30. 177Lu-octreotate really achieve relevant somatostatin receptor saturation in target tumor lesions?: insights from intra-therapeutic receptor imaging in patients with metastatic gastroenteropancreatic neuroendocrine tumors.EJNMMI Res 2013, 3:82.
31. Behe M, Kluge G, Becker W, Gotthardt M, Behr TM: Use of polyglutamic acids to reduce uptake of radiometal-labeled minigastrin in the kidneys.J Nucl Med 2005, 46:1012–1015.
32. Vegt E, Melis M, Eek A, de Visser M, Brom M, Oyen WJ, Gotthardt M, de Jong M, Boerman OC: Renal uptake of different radiolabelled peptides is mediated by megalin: SPECT and biodistribution studies in megalin-deficient mice.Eur J Nucl Med Mol Imaging 2011, 38:623–632.
33. Barone R, Borson-Chazot F, Valkema R, Walrand S, Chauvin F, Gogou L, Kvols LK, Krenning EP, Jamar F, Pauwels S: Patient-specific dosimetry in predicting renal toxicity with (90)Y-DOTATOC: relevance of kidney volume and dose rate in finding a dose-effect relationship.J Nucl Med 2005, 46(Suppl 1):99S–106S.
34. Marks LB, Yorke ED, Jackson A, Ten Haken RK, Constine LS, Eisbruch A, Bentzen SM, Nam J, Deasy JO: Use of normal tissue complication probability models in the clinic.Int J Radiat Oncol Biol Phys 2010, 76:S10–19.
35. Wessels BW, Konijnenberg MW, Dale RG, Breitz HB, Cremonesi M, Meredith RF, Green AJ, Bouchet LG, Brill AB, Bolch WE, Sgouros G, Thomas SR: MIRD pamphlet no. 20: the effect of model assumptions on kidney dosimetry and response–implications for radionuclide therapy.J Nucl Med 2008, 49:1884–1899.
36. Rolleman EJ, Krenning EP, Bernard BF, de Visser M, Bijster M, Visser TJ, Vermeij M, Lindemans J, de Jong M: Long-term toxicity of [(177)Lu-DOTA (0), Tyr (3)]octreotate in rats.Eur J Nucl Med Mol Imaging 2007, 34:219–227.
37. Stewart FA, Oussoren Y, Van Tinteren H, Bentzen SM: Loss of reirradiation tolerance in the kidney with increasing time after single or fractionated partial tolerance doses.Int J Radiat Biol 1994, 66:169–179.
38. Kwekkeboom DJ, de Herder WW, Kam BL, van Eijck CH, van Essen M, Kooij PP, Feelders RA, van Aken MO, Krenning EP: Treatment with the radiolabeled somatostatin analog [177 Lu-DOTA 0, Tyr3]octreotate: toxicity, efficacy, and survival.J Clin Oncol 2008, 26:2124–2130.
39. Pedicini P, Strigari L, Benassi M: Estimation of a self-consistent set of radiobiological parameters from hypofractionated versus standard radiation therapy of prostate cancer.Int J Radiat Oncol Biol Phys 2013, 85:e231–237.
40. O'Donoghue JA, Sgouros G, Divgi CR, Humm JL: Single-dose versus fractionated radioimmunotherapy: model comparisons for uniform tumor dosimetry.J Nucl Med 2000, 41:538–547.